HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
核心洞察
HiRO and Differentia Biotech signed a Memorandum of Understanding to jointly develop AI-powered clinical trial simulation and digital twin capabilities.
The partnership combines HiRO's global clinical operations expertise with Differentia's modeling and simulation platforms to support simulation-first drug development.
The collaboration aims to enable smarter trial design, more efficient patient selection, and potential reduction in the number of subjects needed.
Harvest Integrated Research Organization (HiRO) (搜索), a full-service global clinical research organization (CRO), and Differentia Biotech Ltd. (搜索) ("Differentia"), a pioneer in knowledge-empowered modeling and simulation for drug development, announced a Memorandum of Understanding (MOU) establishing a strategic collaboration between the two companies. The agreement was formalized at HiRO's office in Somerset, N.J., marking a new step in both organizations' efforts to bring more integrated, data-driven solutions to biopharmaceutical sponsors worldwide.
The announcement comes at a time when biopharma R&D productivity is declining and the cost of bringing a single drug to market exceeds $2.6 billion. The partnership unites global clinical operations excellence with advanced digital twin technology, delivering simulation-first drug development to biotech sponsors navigating an era of compressed timelines and escalating trial costs.
Scope of the Collaboration
Under the MOU, HiRO and Differentia will pursue collaboration across two major areas that address the pain points of biotech companies. The first is the joint exploration and development of clinical trial simulation models that combine HiRO's global clinical operations, data science, and real-world data expertise with Differentia's AI-powered digital twin and modeling and simulation platforms. The second is the development of new product offerings and commercial solutions built on those combined simulation capabilities.
The clinical trial simulation collaboration sits at the center of the partnership. By pairing HiRO's operational experience running trials across oncology, rare disease, cell and gene therapy, radiopharmaceuticals, and other complex indications with Differentia's modeling and simulation platforms, the collaboration leverages simulation-informed approaches to support smarter trial design, more efficient patient selection, potential reduction in the number of subjects needed, and better-informed sponsor decision-making earlier in development.
Leadership Perspectives
Chief Executive Officer and Founder of HiRO, Karen Chu, said, "Drug developers don't just need faster trials, they need smarter ones. Differentia's modeling and simulation expertise complements the operational discipline HiRO brings to every study, and this collaboration lets us explore how those strengths work together for the clients we both serve. We are aiming to support our biotech clients in better decision-making."
Founder of Differentia, Shirley Wen, said, "As biopharma R&D productivity continues to decline, clinical development has become an increasingly significant source of cost, time, and risk. As FDA and global regulators increasingly embrace model-informed drug development, the industry must move from 'test in humans first' toward 'simulate first, then test in humans.' Together with HiRO's clinical development expertise, we aim to improve clinical success, reduce trial size, and accelerate time to market—ultimately creating greater value and ROI for every asset."
Chief Executive Officer and Co-Founder of Differentia, Kas Subramanian, said, "By fusing advanced AI and biosimulations with HiRO's industry-leading clinical research expertise, we are creating high-fidelity digital twins that will fundamentally alter the drug development paradigm, allowing biotech pioneers to de-risk assets in a virtual environment and run the most efficient trials."
Strategic Rationale
The collaboration reflects a shared view that sponsors increasingly benefit from pairing disciplined clinical trial execution with advanced modeling and simulation, helping to inform smarter trial design, manage risk, and support timelines across complex therapeutic areas. HiRO brings more than 30 years of collective experience serving small, mid-size, and large biotech and pharma clients, with over 500 professionals and 1,600 trials delivered across 85 countries, combining global reach with regionally informed execution across North America, Europe, APAC, and ANZ. Differentia Bio is a San Francisco-based technology company building the AI-powered digital twin simulation and decision intelligence platform for drug R&D and life sciences, with validated, regulatory-ready simulation capabilities designed to help biopharma decision makers optimize development, accelerate regulatory submissions, and improve the value of their assets and portfolios.
HiRO and Differentia expect to share additional details on specific collaborative initiatives as the partnership progresses.